Company News

Company News
July 21, 2023
Core One Labs Enters into Letter of Intent for First Sale of its Psychedelic Compounds
Vancouver, British Columbia, Canada – July 21, 2023 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (Frankfurt: LD6,...
Read more
Company News
July 19, 2023
Core One Applauds California Assembly Health Committee’s Approval of Bill to Legalize Psychedelics
Vancouver, British Columbia, Canada – July 19, 2023 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6,...
Read more
Company News
July 11, 2023
Core One’s Vocan Biotechnologies Incorporates New Bioreactor Equipment into Production Process Significantly Increasing Throughput of Proprietary Biosynthetic Psilocybin
Vancouver, British Columbia, Canada – July 11, 2023 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU)...
Read more
Company News
July 07, 2023
Core One’s Vocan Files International Patent for its Breakthrough Proprietary Biosynthetic Psilocybin Production Method
Vancouver, British Columbia, Canada – July 7, 2023 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (Frankfurt: LD6,...
Read more
Company News
June 26, 2023
Core One Labs Applauds FDA’s Draft Guidance on Clinical Trials for Psychedelic Drugs
Vancouver, British Columbia, Canada – June 26, 2023 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the...
Read more
Company News
May 05, 2023
Core One in Talks with Multiple Companies to Supply Psilocybin
Vancouver, British Columbia, Canada – May 5, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN:...
Read more